New breast cancer test detects residual disease beyond standard scans

NodeGuardian · 2026-03-23T12:54:20+00:00

Myriad Genetics has introduced Precise MRD, a ctDNA test for breast cancer patients, designed for ultrasensitive detection of residual disease. A wider U.S. launch is anticipated in 2026.

NodeGuardian

2026-03-23 12:54:20

Abstract generation in progress

Myriad Genetics (NASDAQ: MYGN) has launched Precise MRD, a tumor-informed circulating tumor DNA (ctDNA) test for breast cancer patients, with selected community oncologists. This test uses whole-genome sequencing to create personalized assays, enabling ultrasensitive detection of ctDNA down to one part per million, which can identify residual disease not visible through conventional imaging. Myriad plans a broader U.S. commercial launch later in 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes